|
|
Applicatin effect comparison of different dosage of statins in the early stage of acute myocardial infarction |
CHENG Qian-kun |
Department of Circulation,Iron Coal General Hospital,Tieling Health Industry Group,Liaoning Province,Tieling 112700,China |
|
|
Abstract Objective To compare the application effect of different dosage of statins in the early stage of acute myocardial infarction.Methods A total of 60 patients with early stage of acute myocardial infarction treated in our hospital from October 2017 to January 2019 were selected as the subjects.They were divided into experimental group and control group by random number table method,with 30 cases in each group.Patients in the experimental group were treated with Rosuvastatin 20 mg/d,while patients in the control group were treated with Rosuvastatin 10 mg/d,and the patients in both groups were treated for 6 months.The total effective rate,blood lipid index,C-reactive protein,blood pressure and adverse reactions of the two groups were compared.Results The total effective rate of the experimental group was 96.7%,higher than that of the control group(73.3%),the difference was statistically significant(P<0.05).The levels of triacylglycerol,total cholesterol,low density lipoprotein and C-reactive protein in the experimental group were lower than those in the control group,and the level of high density lipoprotein was higher than that in the control group,the differences were statistically significant(P<0.05).The systolic and diastolic blood pressure in the experimental group were lower than those in the control group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the experimental group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion In the early stage of acute myocardial infarction,20 mg/d Rosuvastatin can improve the clinical effect,improve the blood lipid index,C-reactive protein level,reduce the blood pressure,reduce the occurrence of adverse reactions,and have a higher safety.It is worthy of clinical application.
|
|
|
|
|
[1] |
雷锐.不同剂量他汀类药物对早期急性心肌梗死的临床效果和安全性分析[J].中西医结合心脑血管病杂志,2017,15(9):1078-1080.
|
[2] |
马莉.不同剂量他汀类药物治疗急性心肌梗死早期患者的临床疗效分析[J].中国医药指南,2017,15(35):127-128.
|
[3] |
刘长青.不同他汀类药物治疗早发冠心病急性心肌梗死患者近期疗效分析[J].中西医结合心血管病电子杂志,2017,5(14):35.
|
[4] |
金晓萍,张俊杰.他汀类药物对早发冠心病急性心肌梗死患者心脏及血管内皮功能改善研究[J].北华大学学报:自然科学版,2017,18(5):630-632.
|
[5] |
马红,张荣驿,谭春燕,等.不同他汀对急性冠状动脉综合征患者炎症和凋亡反应的作用[J].川北医学院学报,2017,32(1):38-41.
|
[6] |
李宏建.早期启动他汀类药物治疗与延迟治疗相比不能为急性缺血性卒中提供更多优势[J].国际脑血管病杂志,2017,25(5):473.
|
[7] |
张璟轶,梁荻,庞静.急性冠脉综合征急性期他汀类药物治疗方案及剂量选择的临床研究[J].实用临床医药杂志,2017,21(5):18.
|
[8] |
普国全.他汀类药物治疗急性冠脉综合征患者对其肝功能的影响观察[J].中西医结合心血管病电子杂志,2017,5(5):19.
|
[9] |
储新娟,陈阳,侯双兴.他汀类药物联合早期静脉溶栓治疗对急性脑梗死患者神经功能及细胞因子分泌的影响[J].中国医院用药评价与分析,2018,18(7):15-16,20.
|
[10] |
龚倩,黎东,牟英.急性心肌梗死患者二级预防药物应用调查与分析[J].中国卫生产业,2017,14(20):171-173.
|
[11] |
万鹏,付强,张倩,等.他汀类药物对急性ST 段抬高型心肌梗死患者PCSK9 含量的影响[J].江苏大学学报(医学版),2017,27(1):64-68.
|
[12] |
安杰,温盛燕,佘强.负荷他汀类药物对急性ST 段抬高型心肌梗死患者介入治疗术后疗效的Meta 分析[J].第三军医大学学报,2017,39(39):2322.
|
[13] |
彭蕾.他汀类药物对心肌梗死后心脏结构及功能改善的研究进展[J].西北药学杂志,2018,33(2):284-286.
|
[14] |
杨艳丽,乔娟.美托洛尔联合他汀类药物治疗心肌梗死的临床疗效分析[J].中国医药指南,2017,15(12):61-62.
|
[15] |
韩雪娟,靳丽丽,马超,等.不同时间点启动他汀类药物治疗对缺血性卒中患者预后的影响[J].神经损伤与功能重建,2017,12(3):197-199.
|
|
|
|